학술논문

LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis.

Document Type

Article

Author

Shih, J-Y.; Wang, J.; Wang, Y.; Lee, S-H.; Azuma, K.; Takahashi, T.; Tan, J-L.; Lin, C.C.; Ganguly, S.; Lee, V.H.F.; Chu, P-L.; Shah, S.; Diorio, B.; Bauml, J.M.; Cho, B.C.

Source

Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1661-S1662. 2p.

Subject

*ASIANS
*OSIMERTINIB
*SUBGROUP analysis (Experimental design)
*NON-small-cell lung carcinoma
*CANCER chemotherapy

Language

ISSN

0923-7534

Online Access

Full Text (ScienceDirect 종량제) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송